Refine by
Patient Recruitment Articles & Analysis
89 news found
Hemostemix Inc. (TSX-V: HEM; OTCQB: HMTXF; FSE: 2VF0), the leading autologous (patient’s own) stem cell therapy company offering treatments for no-option patients in Florida suffering from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease, Angina, Ischemic Cardiomyopathy, non Ischemic Dilated Cardiomyopathy, and Congestive Heart Failure, is pleased to announce additions to ...
(“Hemostemix” or the “Company”) (TSXV: HEM, OTCQB: HMTXF; FSE:2VF0), the leading autologous (patient’s own) stem cell therapy company treating no-option patients in Florida suffering in pain from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease and Angina, is pleased to announce its webinar topic for Thursday, August ...
The study adds to the evidence obtained in the randomized controlled ROCKET-AF study and supports the use of Xarelto in this patient group, including the cautious use for patients with CKD stage 4 (the use of Xarelto is not recommended in patients with creatinine clearance < 15 ml/min). ...
ByBayer AG
The antibody was transferred to Aulos Bioscience, a Biolojic spinoff that is now conducting clinical trials in Australia and is currently recruiting patients, with hopes of reporting interim data later this year. ...
Lack of funding, safety issues, and patient dropouts are some of the struggles clinical development teams face. ...
The implementation of AIR will aid in the recruitment of patients for clinical trials focused on inflammatory bowel disease (IBD). ...
As clinical trial success relies on effective patient recruitment, BioMark is delighted to announced today that enrollment for its pivotal lung cancer screening study exceeded 1000 participants in less than one year. ...
“Antengene believes that cancer treatments involving the rational combination of immuno-oncology drugs and targeted therapies may offer the greatest opportunity for substantial advances in treatment outcomes for patients with cancer,” said Dr. Amily Zhang, Antengene's Chief Medical Officer. ...
Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with Gastro Health, a national leading medical group specializing in digestive and liver health, to bring its AI Recruitment (AIR) technology to Gastro Health’s practices. This strategic partnership will lay the groundwork for future collaborations by ...
XF-73 Nasal targeting peak sales potential of $1 billion in its major target markets Phase 3 patient recruitment could start in 2024 subject to completing an XF-73 Nasal partnering deal in 2023 XF-73 Nasal is the lead drug candidate developed from Destiny Pharma’s XF platform and it is initially being developed for the prevention of post-surgical ...
First, we will shift from novel target-based discovery to patient-centric medical need research and development with a focus on our key therapeutic areas of immunology and oncology. Second, we will build on our current capabilities and derisk R&D through multiple drug modalities, including CAR-T, and by focusing on best-in-disease validated targets in our strategic ...
Electronic Patient-Reported Outcome Measures (ePROMs) are now allowing these patients to self-report health conditions and treatment effectiveness remotely. This is paving the way for improving patient care as ePROMs can be used to monitor patients with reported health conditions coming directly from the patient, ...
The purpose is to bring new and promising medicines to patients sooner. The Fast Track designation enables ITM to have more frequent interactions with the FDA to discuss the ITM-11 development path. ...
Geneva, Switzerland – October 26th, 2022, STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine platform (DEPI) for patients with Neurodevelopmental Disorders (NDDs), today announced first patient visits in its new STA-B-001 clinical observational-biosampling study in Spain and USA. ...
BySTALICLA
In this new chapter, Iterative Health will continue to focus on its core products, AI Recruitment, SKOUT™, and AI Documentation. AI Recruitment (AI-R) addresses clinical trial recruitment pain points for pharmaceutical companies and clinical research teams working to surface eligible patients for inflammatory bowel disease ...
All comers with advanced cancer will be recruited for Phase I trial. PMC-403 is a novel TIE2-activating antibody that stabilizes dysfunctional leaky disorganized pathological vessels. Wet AMD patients, who are suboptimal responding to Lucentis and Eylea, will be recruited for Phase I trial. PMC-402 is a TIE2-activating antibody that stabilizes ...
Raza, who wrote the best-selling book “The First Cell and the Human Costs of Pursuing Cancer to the Last,” said: “New non-invasive tests are needed to detect the first leukemic cells in the blood of MDS patients so that we can identify and treat patients at risk of developing AML before the disease becomes established.” Patrizia ...
LOS ANGELES, CA – October 6, 2022 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the National Cancer Institute (NCI) and Rutgers University sites are open to recruit patients for the treatment of Kita-Kyushu lung cancer antigen 1 ...
The clinical trial, started in July 2022 and plans to recruit 50 patients eligible for immediate breast reconstruction in 8 centers in Europe. ...
While no significant differences were observed between the groups, average values of HbA1c at baseline, 5 months, and 12 months were lower in patients with HLA DR3-DQ2 compared to the patients lacking HLA DR3-DQ2. ...